Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Recombinant COVID-19 Vaccine(CHO Cell)

Approval Number

国药准字S20220009

Company安徽智飞龙科马生物制药有限公司

Registration Date

February 28, 2023

Drug Information

Generic Name

重组新型冠状病毒蛋白疫苗(CHO细胞)

Trade Name

智克威得

Dosage Form

注射剂

Strength

0.5mL/支，每1次人用剂量为0.5mL，含NCP-RBD蛋白25μg。

Drug Type

生物制品

Registration Date

February 28, 2023

Company Information

Applicant Company

Company Name安徽智飞龙科马生物制药有限公司

Company Address

安徽省合肥市高新区明珠大道5008号

Manufacturing Company

Company Name安徽智飞龙科马生物制药有限公司

Company Address

合肥市高新区浮山路100号

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy

重组新型冠状病毒蛋白疫苗(CHO细胞) - NMPA 批准文号 | MedPath